Skip to main content

Lilly Oncology

2022 Breast Cancer Guide to Patient Support Services

Lilly Oncology Support Center

866-472-8663

Eli Lilly and Company, through Lilly Oncology, offers financial assistance to qualified patients who are prescribed oncology medications and who need help paying for their medications. Support program information for patients taking Verzenio is provided in the Table.

Lilly Oncology Support Center

The Lilly Oncology Support Center provides services to patients and providers, including assistance with infused products, the Verzenio Continuous Care support program, and the Lilly Cares Foundation.

Infused Products Enrollment Form

By enrolling in the Lilly Oncology Support Center, patients may receive various forms of support and information to help access infused oncology products, including benefits investigation support, financial support, and ongoing support. To enroll your patient, complete the application and fax to 877-366-0585.

Verzenio Continuous Care Program

This program provides ongoing support services for patients who have been prescribed Verzenio, including benefits investigation support, the MyRightDose Program, the Companion in Care Program, and other support services. To be eligible for the Verzenio Continuous Care Program, patients must be aged ≥18 years, have been prescribed Verzenio for an FDA-approved indication, and meet the eligibility requirements. To enroll your patient, complete the application and fax to 855-545-5957.

The Verzenio MyRightDose Program allows patients who are prescribed Verzenio to continue therapy with Verzenio at the appropriate dose, without delays or costs to the patient. Verzenio can be shipped to the patients as early as 48 hours after enrollment in the MyRightDose Program. To be eligible for the program, patients must:

  • Return unused pills in the preaddressed envelope, according to the instructions provided
  • Be aged ≥18 years
  • Be a resident of the United States or Puerto Rico
  • Have a prescription for Verzenio for an FDA-approved indication.

The application for the Verzenio MyRightDose Program is available online. The completed form should be faxed to 833-665-6329. Click here for more information on the MyRightDose Program for Verzenio, or call 833-557-2417.

Once enrolled in the Verzenio Continuous Care Program, patients have access to the Companion in Care Program. This program provides patients with help from the same person every time to clarify treatment expectations, provide emotional support, answer questions about side effects, and guide patients back to your practice for medical advice.

Lilly Cares Foundation

The Lilly Cares Foundation provides the Patient Assistance Program for uninsured or underinsured patients who have been prescribed Lilly Oncology medications. Patients may be eligible for this program if they:

  • Are permanent, legal residents of the United States, Puerto Rico, or the US Virgin Islands
  • Have been prescribed a qualifying Lilly medication
  • Have no insurance, or have Medicare Part D
  • Are not enrolled in or have been denied Medicaid, full Low Income Subsidy (LIS, “Extra Help”) or Veterans (VA) Benefits (Humatrope patients with VA and Medicaid benefits may be eligible. Humatrope patients: call Lilly Cares to review eligibility requirements)
  • You meet the household income guidelines for the program.

For more information, please visit LillyCares.com.

TABLE Lilly Breast Cancer Treatment

Drug
Indications
Patient support programs

Drug
Verzenio (abemaciclib) tablets
Indications
Patient support programs

HR indicates hormone receptor; NSCLC, non–small-cell lung cancer.

Verzenio (abemaciclib) tablets Indications

As initial endocrine-based therapy, in combination with an aromatase inhibitor, for postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer; treatment of HR-positive, HER2-negative advanced or metastatic breast cancer, in combination with fulvestrant, for disease that progressed after endocrine therapy; treatment of HR-positive, HER2-negative advanced or metastatic breast cancer, as monotherapy, for disease that progressed after endocrine therapy and previous chemotherapy in the metastatic setting